Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies Patientswho may benefit from enrollment in mechanism-driven clinical trials

Oncologist

Volumn 21, Issue 6, 2016, Pages 684-691

  Suh, James H ^a   Johnson, Adrienne ^a   Albacker, Lee ^a   Wang, Kai ^a,b   Chmielecki, Juliann ^a   Frampton, Garrett ^a   Gay, Laurie ^a   Elvin, Julia A ^a   Vergilio, Jo Anne ^a   Ali, Siraj ^a   Miller, Vincent A ^a   Stephens, Philip J ^a   Ross, Jeffrey S ^a  

^a FOUNDATION MEDICINE   (United States)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Clinical trials; Comprehensive genomic profiling; National comprehensive cancer network guidelines; Non small cell lung cancer

Indexed keywords

AFATINIB; ALECTINIB; CABOZANTINIB; CERITINIB; CRIZOTINIB; DABRAFENIB; ERLOTINIB; GEFITINIB; TRAMETINIB; TRASTUZUMAB; VEMURAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CLINICAL TRIAL; EGFR GENE; ERBB2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; KRAS GENE; LUNG ADENOCARCINOMA; MALE; MET GENE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RET GENE; ROS1 GENE; VERY ELDERLY; CLINICAL TRIAL (TOPIC); GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MIDDLE AGED; MUTATION; PATIENT PARTICIPATION; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATIENT PARTICIPATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84975259981     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0030     Document Type: Article

References (48)

1. AmericanCancer Society. Cancer Facts& Figures 2015. Available at http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed November 2, 2015, 2016.
2. Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res 2009;315:557-571.
3. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
4. Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
5. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8: 823-859.
6. Leighl NB, Rekhtman N, Biermann WA et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College ofAmerican Pathologists/International Association for the Study of Lung Cancer/Association forMolecular Pathology Guideline. J Clin Oncol 2014;32:3673-3679.
7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Non-small cell lung cancer. 2016. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
8. Gautschi O, Pauli C, Strobel K et al. Apatient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-e24.
9. Planchard D, Mazieres J, Riely GJ et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013;31: 8009a.
10. Ou S-HI, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymale pithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novoMETamplification. J Thorac Oncol 2011;6:942-946.
11. Camidge DR, Ou S-HI, Shapiro G et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32:8001a.
12. Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl JMed 2015;372:683-684.
13. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354: 2619-2621.
14. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003.
15. Drilon A, Wang L, Hasanovic A et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3: 630-635.
16. Drilon A, Wang L, Arcila ME et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015;21:3631-3639.
17. Khoo C, Rogers T-M, Fellowes A et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res 2015;4:126-141.
18. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-1031.
19. Cheng DT, Mitchell TN, Zehir A et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251-264.
20. Ross JS, Wang K, Chmielecki J et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer 2016; 138:881-890.
21. Vaishnavi A, Capelletti M, Le AT et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-1472.
22. Fernandez-Cuesta L, Plenker D, Osada H et al. CD74-NRG1fusions in lungadenocarcinoma. Cancer Discov 2014;4:415-422.
23. Frampton GM, Ali SM, Rosenzweig M et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5:850-859.
24. Paik PK, Drilon A, Fan P-D et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-849.
25. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: Strategic management of tissue for molecular testing. Semin Respir Crit CareMed 2011; 32:22-31.
26. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: A practical guide. Am J Clin Pathol 2012;138:332-346.
27. Shaw AT, Ou S-HI, Bang Y-J et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl JMed 2014;371:1963-1971.
28. Sholl LM, Aisner DL, Varella-Garcia M et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-777.
29. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma [published correction appears in Nature 2014;514(7521):262]. Nature 2014;511:543-550.
30. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18: 4910-4918.
31. Li C, Sun Y, Fang R et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol 2012;7: 85-89.
32. Dogan S, Shen R, Ang DC et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012;18:6169-6177.
33. Spicer J, Tischer B, Peters M. EGFR mutation testing and oncologist treatmentchoice in advanced NSCLC: Global trends and differences. Ann Oncol 2015;26(suppl 1):i60.
34. Catalogue of Somatic Mutations in Cancer (COSMIC). COSMIC database. Available at cancer. sanger.ac.uk/cosmic. Accessed November 2, 2015.
35. Klempner SJ, Bazhenova LA, Braiteh FS et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer 2015; 89:357-359.
36. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl JMed 2010;363:1734-1739.
37. Friboulet L, Li N, Katayama R et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4: 662-673.
38. Ou S-HI, Klempner SJ, Greenbowe JR et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol 2014;9:1821-1825.
39. Katayama R, Friboulet L, Koike S et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014;20:5686-5696.
40. Ali SM, Ou S-HI, He J et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. J Clin Oncol 2014;32:8049a.
41. Schrock AB, Frampton GM, Herndon D et al. Comprehensive genomic profiling identifies frequent drug sensitive EGFR exon 19 deletions in NSCLC not identified by priormolecular testing. Clin Cancer Res 2016 [Epub ahead of print].
42. Farago AF, Le LP, Zheng Z et al. Durable clinical response to entrectinib in NTRK1-rearranged nonsmall cell lung cancer. J Thorac Oncol 2015;10: 1670-1674.
43. Cheng H, Zou Y, Ross JS et al. RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov 2015;5: 1262-1270.
44. Yarmus L, Akulian J, Gilbert C et al. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed? Ann Am Thorac Soc 2013;10:636-643.
45. Sheth S, Jilani D, Bos A et al. Core lung biopsy for biomarker analysis: Is there increased risk compared with conventional biopsy? J Thorac Imaging 2015;30: 314-318.
46. Heymann JJ, Bulman WA, Maxfield RA et al. Molecular testing guidelines for lung adenocarcinoma: Utility ofcell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal 2014;11:12.
47. Young G, Wang K, He J et al. Clinical nextgeneration sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013;121: 688-694.
48. Blumenthal GM, Mansfield E, Pazdur R. Nextgeneration sequencing in oncology in the era of precision medicine. JAMA Oncol 2016;2:13-14.